請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/80832完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 鄧述諄(Shu-Chun Teng) | |
| dc.contributor.author | Shan-Chi Yu | en |
| dc.contributor.author | 尤善琦 | zh_TW |
| dc.date.accessioned | 2022-11-24T03:18:17Z | - |
| dc.date.available | 2021-11-05 | |
| dc.date.available | 2022-11-24T03:18:17Z | - |
| dc.date.copyright | 2021-11-05 | |
| dc.date.issued | 2021 | |
| dc.date.submitted | 2021-10-05 | |
| dc.identifier.citation | 1. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010; 202-13. 2. Zuhair M, Smit GSA, Wallis G, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. Rev Med Virol. 2019; e2034. 3. Lu SC, Chin LT, Wu FM, et al. Seroprevalence of CMV antibodies in a blood donor population and premature neonates in the south-central Taiwan. Kaohsiung J Med Sci. 1999; 603-10. 4. Chen MH, Chen PC, Jeng SF, et al. High perinatal seroprevalence of cytomegalovirus in northern Taiwan. J Paediatr Child Health. 2008; 166-9. 5. Krishna BA, Wills MR, Sinclair JH. Advances in the treatment of cytomegalovirus. Br Med Bull. 2019; 5-17. 6. Fakhreddine AY, Frenette CT, Konijeti GG. A Practical Review of Cytomegalovirus in Gastroenterology and Hepatology. Gastroenterol Res Pract. 2019; 6156581. 7. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev. 2009; 76-98. 8. Einsele H, Ljungman P, Boeckh M. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood. 2020; 1619-29. 9. Slade M, Goldsmith S, Romee R, et al. Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. Transpl Infect Dis. 2017; e12629. 10. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003; 543-58. 11. Jerry Teng CL, Wang PN, Chen YC, Ko BS. Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review. J Microbiol Immunol Infect. 2021; 341-8. 12. Cho SY, Lee DG, Kim HJ. Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy. Int J Mol Sci. 2019; 2666. 13. Lin CH, Su YJ, Hsu CY, Wang PN, Teng CJ. Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia. Transpl Infect Dis. 2019; e13096. 14. Sinzger C, Digel M, Jahn G. Cytomegalovirus cell tropism. Curr Top Microbiol Immunol. 2008; 63-83. 15. Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. Clin Infect Dis. 2017; 87-91. 16. Lancini D, Faddy HM, Flower R, Hogan C. Cytomegalovirus disease in immunocompetent adults. Med J Aust. 2014; 578-80. 17. Ferry JA. Reactive Lymph Nodes and Castleman Disease. In: Hsi ED, ed. Hematopathology. Philadelphia: Elsevier:118-66. 18. Wang SA. Cytomegalovirus lymphadenitis. In: Medeiros LJ, Miranda RN, Wang SA, et al., eds. Diagnostic pathology lymph nodes and spleen with extranodal lymphomas: Amirsys, 2011:2-86. 19. Ioachim HL, Medeiros LJ. Cytomegalovirus lymphadenitis. Ioachim's lymph node pathology. 3rd ed. Philadelphia, PA: Lippincott Williams Wilkins, 2002:83. 20. Hsi ED, Schnitzer B. Reactive lymphadenopathies. In: Jaffe ES, Arber DA, Campo E, Harris NL, Quintanilla-Martinez L, eds. Hematopathology. 2nd ed. Philadelphia, PA: Elsevier, 2017:153. 21. Wreghitt TG, Teare EL, Sule O, Devi R, Rice P. Cytomegalovirus infection in immunocompetent patients. Clin Infect Dis. 2003; 1603-6. 22. Ishii T, Sasaki Y, Maeda T, Komatsu F, Suzuki T, Urita Y. Clinical differentiation of infectious mononucleosis that is caused by Epstein-Barr virus or cytomegalovirus: A single-center case-control study in Japan. J Infect Chemother. 2019; 431-6. 23. Rushin JM, Riordan GP, Heaton RB, Sharpe RW, Cotelingam JD, Jaffe ES. Cytomegalovirus-infected cells express Leu-M1 antigen. A potential source of diagnostic error. Am J Pathol. 1990; 989-95. 24. Joubert M, Morin C, Moreau A, Heymann MF, Laboisse C, Gaillard F. [Histopathologic features of cytomegalovirus lymphadenitis in the 'immunocompetent' patient. Report of 7 cases]. Ann Pathol. 1996; 254-60. 25. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010; 1824-33. 26. Klairmont MM, Gradowski JF. Hiding in the mantle: mantle cell lymphoma with a mantle zone growth pattern co-occurring with CMV lymphadenitis. Blood. 2019; 1683. 27. Lum EL, Schaenman JM, DeNicola M, Reddy UG, Shen JI, Pullarkat ST. A case report of CMV lymphadenitis in an adult kidney transplant recipient. Transplant Proc. 2015; 141-5. 28. Kang KW, Lee JH, Choi JS, et al. Spontaneous resolution of post-transplant localized cytomegalovirus lymphadenitis mimicking tumor recurrence. Transpl Infect Dis. 2014; 676-80. 29. Roe CJ, Siddiqui MT, Lawson D, Cohen C. RNA In Situ Hybridization for Epstein-Barr Virus and Cytomegalovirus: Comparison With In Situ Hybridization and Immunohistochemistry. Appl Immunohistochem Mol Morphol. 2019; 155-9. 30. Mills AM, Guo FP, Copland AP, Pai RK, Pinsky BA. A comparison of CMV detection in gastrointestinal mucosal biopsies using immunohistochemistry and PCR performed on formalin-fixed, paraffin-embedded tissue. Am J Surg Pathol. 2013; 995-1000. 31. Solomon IH, Hornick JL, Laga AC. Immunohistochemistry Is Rarely Justified for the Diagnosis of Viral Infections. Am J Clin Pathol. 2017; 96-104. 32. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. Jama. 2008; 413-22. 33. Green ML, Leisenring WM, Xie H, et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood. 2013; 1316-24. 34. Cook GJ, Wegner EA, Fogelman I. Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med. 2004; 122-33. 35. Kjaer ASL, Ribberholt I, Thomsen K, Ibsen PH, Markova E, Graff J. (18)F-FDG PET/CT Findings in Cytomegalovirus Colitis. Diagnostics (Basel). 2018; 3. 36. Nihashi T, Ito K, Kato T, et al. An abnormal accumulation of fluorine-18-FDG PET in cytomegalovirus enteritis--a case report. Ann Nucl Med. 2006; 75-8. 37. Banzo J, Ubieto MA, Prats E, et al. [¹⁸F-FDG PET-CT in cytomegalovirus-induced mononucleosis]. Rev Esp Med Nucl. 2010; 304-7. 38. Thanarajasingam G, Bennani-Baiti N, Thompson CA. PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma. Curr Treat Options Oncol. 2016; 24. 39. Yu Y, Maguire TG, Alwine JC. ChREBP, a glucose-responsive transcriptional factor, enhances glucose metabolism to support biosynthesis in human cytomegalovirus-infected cells. Proc Natl Acad Sci U S A. 2014; 1951-6. 40. Yu Y, Clippinger AJ, Alwine JC. Viral effects on metabolism: changes in glucose and glutamine utilization during human cytomegalovirus infection. Trends Microbiol. 2011; 360-7. 41. Hudnall SD, Ge Y, Wei L, Yang NP, Wang HQ, Chen T. Distribution and phenotype of Epstein-Barr virus-infected cells in human pharyngeal tonsils. Mod Pathol. 2005; 519-27. 42. Niedobitek G, Herbst H, Young LS, et al. Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. Blood. 1992; 2520-6. 43. Dojcinov SD, Venkataraman G, Pittaluga S, et al. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood. 2011; 4726-35. 44. Mohamed G, Vrzalikova K, Cader FZ, et al. Epstein-Barr virus, the germinal centre and the development of Hodgkin's lymphoma. J Gen Virol. 2014; 1861-9. 45. Kojima M, Kashimura M, Itoh H, et al. Epstein-Barr virus-related reactive lymphoproliferative disorders in middle-aged or elderly patients presenting with atypical features. A clinicopathological study of six cases. Pathol Res Pract. 2007; 587-91. 46. Fanaian NK, Cohen C, Waldrop S, Wang J, Shehata BM. Epstein-Barr virus (EBV)-encoded RNA: automated in-situ hybridization (ISH) compared with manual ISH and immunohistochemistry for detection of EBV in pediatric lymphoproliferative disorders. Pediatr Dev Pathol. 2009; 195-9. 47. Liao X, Reed SL, Lin GY. Immunostaining Detection of Cytomegalovirus in Gastrointestinal Biopsies: Clinicopathological Correlation at a Large Academic Health System. Gastroenterology Res. 2016; 92-8. 48. Yan Z, Wang L, Dennis J, Doern C, Baker J, Park JY. Clinical significance of isolated cytomegalovirus-infected gastrointestinal cells. Int J Surg Pathol. 2014; 492-8. 49. Kojima M, Nakamura S, Itoh H, et al. Occurrence of monocytoid B-cells in reactive lymph node lesions. Pathol Res Pract. 1998; 559-65. 50. Kojima M, Kashimura M, Itoh H, et al. Infectious mononucleosis lymphoadenitis showing histologic findings indistinguishable from toxoplasma lymphadenitis. A report of three cases. Pathol Res Pract. 2010; 361-4. 51. Anagnostopoulos I, Hummel M, Falini B, Joehrens K, Stein H. Epstein-barr virus infection of monocytoid B-cell proliferates: an early feature of primary viral infection? Am J Surg Pathol. 2005; 595-601. 52. Shimada K, Hayakawa F, Kiyoi H. Biology and management of primary effusion lymphoma. Blood. 2018; 1879-88. 53. Altan-Bonnet G, Mukherjee R. Cytokine-mediated communication: a quantitative appraisal of immune complexity. Nat Rev Immunol. 2019; 205-17. 54. van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018; 213-28. 55. Crawford LB, Streblow DN, Hakki M, Nelson JA, Caposio P. Humanized mouse models of human cytomegalovirus infection. Curr Opin Virol. 2015; 86-92. 56. Wagar LE, Salahudeen A, Constantz CM, et al. Modeling human adaptive immune responses with tonsil organoids. Nat Med. 2021; 125-35. 57. Nelson BP, Wolniak KL, Evens A, Chenn A, Maddalozzo J, Proytcheva M. Early posttransplant lymphoproliferative disease: clinicopathologic features and correlation with mTOR signaling pathway activation. Am J Clin Pathol. 2012; 568-78. 58. Aguilera N, Gru AA. Reexamining post-transplant lymphoproliferative disorders: Newly recognized and enigmatic types. Semin Diagn Pathol. 2018; 236-46. 59. Vakiani E, Nandula SV, Subramaniyam S, et al. Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion. Hum Pathol. 2007; 315-25. 60. Gallach M, Mikhail Lette M, Abdel-Wahab M, Giammarile F, Pellet O, Paez D. Addressing Global Inequities in Positron Emission Tomography-Computed Tomography (PET-CT) for Cancer Management: A Statistical Model to Guide Strategic Planning. Med Sci Monit. 2020; e926544. 61. Yu SC, Ko KY, Teng SC, Huang TC, Lo HT, Cheng CL, Yao M, Hong RL, Chen CN, Chen TC, Yang TL. A Clinicopathological Study of Cytomegalovirus Lymphadenitis and Tonsillitis Their Association with Epstein-Barr Virus. Infect Dis Ther. In Press. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/80832 | - |
| dc.description.abstract | "巨細胞病毒淋巴炎的組織病理特徵已廣為描述，然鮮有此病臨床特徵與病人免疫狀態之研究。多數專家相信巨細胞病毒淋巴炎在免疫低下與免疫健全的人體皆可發生。此病最廣為人知的臨床表現是類似感染性單核球症的徵候群。本研究從庫存病理玻片中，回顧在淋巴組織做的巨細胞病毒免疫組織化學染色，研究巨細胞病毒陽性案例的臨床病理特徵。結果發現在淋巴結組織，29% (5/17)的異體周邊血造血幹細胞受贈者、29% (4/14)曾接受自體周邊血造血幹細胞的病患、13% (6/47)曾接受靜脈注射化學治療的病患以及9% (9/96)免疫健全者，有偵測到巨細胞病毒。7% (2/24)的扁桃腺有偵測到巨細胞病毒，但是在鼻咽、舌底或脾臟則偵測不到。這些巨細胞病毒陽性的病人，有醫源性免疫低下者，年齡在37到76歲間，這些病人的巨細胞病毒感染在淋巴癌治療數年後發生(中位期間：異體周邊血造血幹細胞後932天、自體周邊血造血幹細胞後370天、化學治療後626天)。研究案例中最常見的臨床表現是頸部腫塊(13/25, 42%)，其次為無症狀的影像學發現(10/25, 40%)。曾接受正子斷層掃描的所有病人，患處都呈現高於肝臟的吸收值(11/11, 100%)，其中80% (8/10)的淋巴癌病患依照多維爾標準評為4到5分。在淋巴癌病患以正子斷層掃描追蹤復發的偽陽性案例中，這些案例佔高達30% (8/27)。本研究所有案例皆自行痊癒。此外，96% (23/25)的案例同時有EB病毒感染，且EBER陽性細胞集中在少數生發中心內。總結來說，巨細胞病毒淋巴炎與扁桃腺炎屬於亞急性感染，並非巨細胞病毒初次感染造成的類似感染性單核球症的徵候群。典型的臨床面貌是中老年淋巴癌病人治療後數年後的淋巴結病變，在淋巴癌治療後追蹤的正子斷層造影結果貌似淋巴癌復發。因此辨識出淋巴組織的巨細胞病毒感染具有臨床重要性。" | zh_TW |
| dc.description.provenance | Made available in DSpace on 2022-11-24T03:18:17Z (GMT). No. of bitstreams: 1 U0001-0110202112270800.pdf: 4127795 bytes, checksum: 3d4bc76d649e63d94b6a2dd3b76d0ba4 (MD5) Previous issue date: 2021 | en |
| dc.description.tableofcontents | 口試委員審定書 i 序言 ii 摘要 iii Abstract iv Introduction 1 Methods 2 Results 4 CMV prevalence in lymphoid tissues 4 Patient characteristics 5 Clinical differences between CMV-positive and -negative cases 5 Clinical presentation and PET/CT scan results 6 Histopathological characteristics 7 Discussion 8 Immune status of patients 9 Clinical presentation 9 PET scan 9 EBV coinfection 11 Limitations 13 Conclusions 14 參考文獻 23 附錄 30 | |
| dc.language.iso | en | |
| dc.subject | 正子斷層掃描 | zh_TW |
| dc.subject | 巨細胞病毒 | zh_TW |
| dc.subject | 良性淋巴增生 | zh_TW |
| dc.subject | 淋巴腫大 | zh_TW |
| dc.subject | 淋巴癌 | zh_TW |
| dc.subject | EB病毒 | zh_TW |
| dc.subject | cytomegalovirus | en |
| dc.subject | lymphadenopathy | en |
| dc.subject | positron emission tomography | en |
| dc.subject | reactive lymphoid hyperplasia | en |
| dc.subject | lymphoma | en |
| dc.subject | Epstein-Barr virus | en |
| dc.title | 巨細胞病毒淋巴炎與扁桃腺炎的臨床病理研究及其與EB病毒之關聯性 | zh_TW |
| dc.title | A Clinicopathological of Cytomegalovirus Lymphadenitis and Tonsillitis and Their Association with Epstein-Barr virus | en |
| dc.date.schoolyear | 109-2 | |
| dc.description.degree | 博士 | |
| dc.contributor.author-orcid | 0000-0002-3642-2788 | |
| dc.contributor.oralexamcommittee | 陳美如(Hsin-Tsai Liu),林敬哲(Chih-Yang Tseng),林靜嫻,吳青錫 | |
| dc.subject.keyword | 正子斷層掃描,巨細胞病毒,良性淋巴增生,淋巴腫大,淋巴癌,EB病毒, | zh_TW |
| dc.subject.keyword | cytomegalovirus,Epstein-Barr virus,lymphoma,lymphadenopathy,positron emission tomography,reactive lymphoid hyperplasia, | en |
| dc.relation.page | 42 | |
| dc.identifier.doi | 10.6342/NTU202103493 | |
| dc.rights.note | 同意授權(限校園內公開) | |
| dc.date.accepted | 2021-10-05 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-0110202112270800.pdf 授權僅限NTU校內IP使用（校園外請利用VPN校外連線服務） | 4.03 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。